Kapur Anil 4

What Happened
Anil Kapur, a director of Nurix Therapeutics, received a derivative equity award for 31,250 shares on 2026-05-15. The filing lists the acquisition price as $0.00 (reporting code A — grant/award). This is an equity award that does not represent an immediate open-market purchase or sale by the insider.

Key Details

• Transaction date: 2026-05-15 (reported same day).
• Amount: 31,250 shares recorded as a derivative award; price reported $0.00.
• Shares owned after transaction: Not disclosed in this Form 4.
• Vesting/conditions: Footnote states the award vests 100% on the earlier of the next annual stockholder meeting or May 15, 2027, subject to Kapur’s continued service on the vesting date.
• Filing timeliness: Reported on the filing date (no late filing indicated).

Context
This is a grant/award (derivative) rather than a market purchase or sale. The award appears subject to time-based vesting and does not indicate any immediate sale or cashless exercise; until vesting, the economic or voting rights may be limited. Such grants are common for directors as compensation and are not a direct buy/sell signal of short-term market views.